SCHEMBL3593612

SCHEMBL3593612

CN(C(=O)O)C1CCN(CCc2cc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 3/20 0.47
DRD3 P35462 3/20 0.47
DRD2 P14416 2/20 0.47
POLB P06746 1/20 0.46
NOTUM Q6P988 2/20 0.44
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
CCR5 P51681 2/20 0.43
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PRCP P42785 1/20 0.43
JAK2 O60674 1/20 0.43
UCHL1 P09936 1/20 0.42
USP30 Q70CQ3 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
RAB9A P51151 2/20 0.42
OPRM1 P35372 1/20 0.41
F10 P00742 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594360 0.94 DRD2 (0.45) DRD4DRD3DRD2POLBNOTUM
SCHEMBL3606182 0.92 DRD2 (0.51) DRD4DRD3DRD2POLBNOTUM
SCHEMBL5709416 0.88 DRD4 (0.45) DRD4DRD3DRD2POLBNOTUM
SCHEMBL3594728 0.83 NOTUM (0.45) DRD4DRD3DRD2POLBNOTUM
SCHEMBL3593611 0.80 USP30 (0.50) DRD4DRD3DRD2POLBNOTUM
SCHEMBL5484406 0.80 NOTUM (0.51) DRD4DRD3DRD2POLBNOTUM
SCHEMBL3605749 0.79 NOTUM (0.44) DRD4DRD3DRD2POLBNOTUM
SCHEMBL2981408 0.79 POLB (0.42) DRD4DRD3DRD2POLBNOTUM
SCHEMBL3938772 0.78 CHRM4 (0.49) DRD4DRD3DRD2POLBNOTUM
SCHEMBL5709438 0.78 POLB (0.47) DRD4DRD3DRD2POLBNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 DRD4 2463/4885DRD3 1682/4885DRD2 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.